Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.

Cancer research - 15 Nov 2001

Parajuli P, Pisarev V, Sublet J, Steffel A, Varney M, Singh R, LaFace D, Talmadge J E

Abstract excerpt

We examined the ability of immunization with sequential adenovirus/plasmid DNA vectors expressing human wild-type p53 to stimulate a type 1 T-cell response and induce protection against challenge from a metastatic tumor that expresses mutated murine p53. We found that tumor protection and an antigen (Ag)-specific immune response were enhanced by prior injection of Flt3 ligand (Flt3L) at a dose and schedule that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Dendritic Cells

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epitopes, T-Lymphocyte

Share to Hypersensitivity, Delayed

Share to Immunization

Share to Interleukins

Share to Mammary Neoplasms, Experimental

Share to Spleen

Source

Identifiers

PMID: 11719454

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.PMID 11719454Read ↗

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.Semantic proximity Read ↗

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Semantic proximity Read ↗

CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.Semantic proximity Read ↗

p53: a potential target antigen for immunotherapy of cancer.Semantic proximity Read ↗

Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53.Semantic proximity Read ↗

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.Semantic proximity Read ↗

Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.Semantic proximity Read ↗

Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesSemantic proximity Read ↗

Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Semantic proximity Read ↗

Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells.Semantic proximity Read ↗

Idiotypic immunization induces immunity to mutated p53 and tumor rejection.Semantic proximity Read ↗

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.